EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ABL Bio's Enterprise Value is ₩1,137,409 Mil.
ABL Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-37,465 Mil. Therefore, ABL Bio's EV-to-EBIT for today is -30.36.
The historical rank and industry rank for ABL Bio's EV-to-EBIT or its related term are showing as below:
XKRX:298380'
s EV-to-EBIT Range Over the Past 10 Years
Min: -2676.58 Med: -21.13 Max: 253.02
Current: -30.36
During the past 8 years, the highest EV-to-EBIT of ABL Bio was 253.02. The lowest was -2676.58. And the median was -21.13.
XKRX:298380's EV-to-EBIT is ranked worse than 100% of 421
companies
in the Biotechnology industry
Industry Median: 10.43
vs XKRX:298380: -30.36
The historical data trend for ABL Bio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ABL Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Bio's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ABL Bio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ABL Bio's EV-to-EBIT falls into.
ABL Bio's current Enterprise Value is ₩1,137,409 Mil.
ABL Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-37,465 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Bio (XKRX:298380) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ABL Bio's Enterprise Value for the quarter that ended in Mar. 2024 was ₩1,288,270 Mil.
ABL Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-37,465 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Bio EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of ABL Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:298380 has been successfully added to your 